Meeder Advisory Services’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.42M Sell
34,965
-847
-2% -$112K 0.16% 86
2026
Q1
$4.99M Buy
35,812
+1,722
+5% +$241K 0.21% 73
2025
Q4
$4.18M Buy
34,090
+1,684
+5% +$205K 0.18% 83
2025
Q3
$3.6M Buy
32,406
+747
+2% +$84.9K 0.17% 94
2025
Q2
$3.51M Buy
31,659
+1,865
+6% +$198K 0.18% 87
2025
Q1
$3.34M Buy
29,794
+2,049
+7% +$211K 0.2% 83
2024
Q4
$2.56M Buy
27,745
+2,073
+8% +$187K 0.16% 104
2024
Q3
$2.15M Sell
25,672
-147
-0.6% -$11.2K 0.14% 118
2024
Q2
$1.77M Buy
25,819
+3,802
+17% +$254K 0.13% 133
2024
Q1
$1.61M Buy
22,017
+1,209
+6% +$93K 0.16% 107
2023
Q4
$1.69M Buy
20,808
+585
+3% +$45.5K 0.19% 89
2023
Q3
$1.52M Sell
20,223
-3,903
-16% -$300K 0.19% 87
2023
Q2
$1.86M Buy
24,126
+1,761
+8% +$140K 0.2% 90
2023
Q1
$1.86M Buy
22,365
+1,190
+6% +$98.6K 0.21% 85
2022
Q4
$1.82M Buy
+21,175
New +$1.68M 0.23% 81

Other funds holding GILD

Meeder Advisory Services's GILD Position: Q2 2026 in Review

Meeder Advisory Services reduced its Gilead Sciences (GILD) stake by 2.4% in Q2 2026, selling an estimated $112K and leaving 34,965 shares worth $4.42M. The position accounts for 0.16% of the portfolio, ranked #86.

Meeder Advisory Services first reported a position in GILD in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.99M in Q1 2026. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Meeder Advisory Services held 34,965 shares of Gilead Sciences worth $4.42M as of Q2 2026.
  • Meeder Advisory Services sold 847 Gilead Sciences shares in Q2 2026, an estimated $112K.
  • Gilead Sciences made up 0.16% of Meeder Advisory Services's portfolio in Q2 2026, its #86 holding.
  • Meeder Advisory Services first reported a position in Gilead Sciences in Q4 2022 and has held it in 15 quarters since.
  • Meeder Advisory Services's Gilead Sciences position peaked at $4.99M in Q1 2026.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Meeder Advisory Services's 13F filing for Q2 2026, filed 7 Aug 2026.